8-K: Avid Bioservices Reports Strong Q1 Results with Increased Revenue and Backlog

Avid Bioservices announced a 6% increase in first-quarter revenue to $40.2 million and a 16% increase in backlog to $219 million, driven by new customer acquisitions and strong process development revenue.

Summary

• Avid Bioservices reported its financial results for the first quarter ended July 31, 2024.
• The company's revenue for the quarter was $40.2 million, a 6% increase compared to $37.7 million in the same period last year.
• This increase was primarily due to higher process development revenues.
• The company signed $66 million in net new business, resulting in a backlog of $219 million, a 16% increase year-over-year.
• Gross profit for the quarter was $5.7 million, with a gross margin of 14%, compared to $4.1 million and 11% in the prior year.
• SG&A expenses increased by 30% to $8.2 million, primarily due to higher compensation and consulting fees.
• The company reported a net loss of $5.5 million, or $0.09 per share, compared to a net loss of $2.1 million, or $0.03 per share, in the same quarter last year.
• Avid Bioservices is maintaining its fiscal year 2025 revenue guidance of $160 million to $168 million.
• The company had $33.4 million in cash and cash equivalents as of July 31, 2024.

Sentiment

Score: 7

Explanation: The sentiment is positive due to strong revenue growth, a significant increase in backlog, and improved gross margins. However, the increased net loss and SG&A expenses temper the overall sentiment.

Positives

• The company experienced strong revenue growth, driven by increased process development activities.
• The company secured a substantial amount of new business, significantly increasing its backlog.
• Gross profit margins improved, indicating better cost management and operational efficiency.
• The company is attracting a diverse range of customers, including large pharmaceutical companies.
• The company is progressing with projects from early-stage development to commercialization.
• The company's investments in infrastructure and capabilities are attracting new business opportunities.

Negatives

• The company's net loss increased to $5.5 million, compared to $2.1 million in the same quarter last year.
• SG&A expenses increased by 30%, primarily due to higher compensation and consulting fees.
• Cash and cash equivalents decreased from $38.1 million to $33.4 million during the quarter.

Risks

• The company may experience delays in engaging new customers.
• There is a risk that the company may not be successful in executing customer projects.
• Changing economic conditions may delay or adversely impact the realization of the company's backlog.
• The company may not be able to convert its backlog into revenue within the anticipated time periods.
• Technical difficulties in completing customer projects could result in project terminations or delays.
• Later-stage customers may not receive regulatory approval or commercial demand may be less than forecast.
• Existing customers may terminate contracts or reduce demand, affecting revenue.
• Expanding into new areas like cell and gene therapy may distract from existing operations.
• There may be delays in hiring qualified individuals for the cell and gene therapy business.
• The cell and gene therapy business may not become profitable for several years, if ever.

Future Outlook

The company expects revenues and capacity utilization to increase, generating higher margins, and positioning Avid to achieve strong growth going forward. They are maintaining their fiscal year 2025 revenue guidance of $160 million to $168 million.

Management Comments

• Nick Green, president and CEO of Avid Bioservices, stated that the first quarter continued the strong momentum seen since the completion of their expansion program.
• He also noted that the company is encouraged by the strong revenues and new business signings, which continue to build their backlog and improve margins.
• Management is focused on filling the remaining capacity and expects revenues and capacity utilization to increase.

Industry Context

This announcement reflects the ongoing demand for contract development and manufacturing services in the biologics sector. Avid's focus on expanding its customer base and project pipeline aligns with industry trends towards outsourcing manufacturing to specialized CDMOs.

Comparison to Industry Standards

• Avid's 6% revenue growth is a positive sign in the competitive CDMO market, but it is important to compare this to other similar companies such as Catalent, Lonza, and Samsung Biologics.
• The 16% increase in backlog is a strong indicator of future revenue potential, and should be compared to the backlog growth of its peers.
• The gross margin of 14% is a key metric to watch, as it reflects the company's ability to manage costs and generate profit from its services. This should be compared to the gross margins of other CDMOs.
• The net loss of $5.5 million is a concern, and should be compared to the profitability of other CDMOs. Companies like Lonza and Samsung Biologics are generally profitable, while smaller CDMOs may be in a growth phase and not yet profitable.

Stakeholder Impact

• Shareholders will be encouraged by the revenue growth and backlog increase, but concerned about the increased net loss.
• Employees may benefit from the company's growth and expansion.
• Customers will benefit from the company's expanded capabilities and services.
• Suppliers may see increased business opportunities due to the company's growth.

Next Steps

• The company will continue to focus on filling its remaining capacity.
• The company will execute on its backlog and leverage its reputation in the industry.
• The company will continue to diversify its customer base and project pipeline.
• The company will host a webcast to discuss the financial results.

Key Dates

Keywords

CDMO, biologics, contract manufacturing, revenue, backlog, process development, gross profit, net loss, pharmaceutical, biotechnology